On October 27, 2021 Aston Sci., a portfolio model biopharmaceutical company, reported that the study results of its therapeutic cancer vaccine pipelines, AST-301 and AST-021p, will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)(SITC) in November (Press release, Aston Sci, OCT 27, 2021, View Source [SID1234592070]). The respective abstract for AST-301 and AST-021p were accepted by the SITC (Free SITC Whitepaper).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The data from the study of AST-301, a pDNA-based cancer vaccine, using mice models with HER2-expressing gastric cancer shows the efficacy of monotherapy and combination therapy of the vaccine. At the 2021 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) in June, Aston Sci. demonstrated the medical efficacy and long-term safety of AST-301 through the results from phase 1 clinical trials on 66 patients with HER2-positive advanced breast cancer. AST-301 is currently under IND review by the Ministry of Food and Drug Safety for subsequent clinical trials.
Aston Sci. also presents the efficacy of combination therapy of AST-021p using a breast cancer mouse model. AST-021p is an investigational therapeutic cancer vaccine composed of two different peptides which are derived from HLA class II binding epitopes of human HSP90 protein. The results of comparative evaluation on tumor growth inhibition and immunogenicity when used in combination with several immune adjuvants, including "L-pampo" (TLR-2/3 ligand-based immune adjuvant) in-licensed from the CHA Vaccine Institute, will be presented. Currently, AST-021p is in phase 1 clinical trial for recurrent or advanced solid tumors for which there is no standard treatment.
"As cancer has become a disease requiring more prevention and management due to technological advances in early diagnosis, the need for adjuvant therapy for early cancer treatment and prevention of recurrence after surgery has increased. Aston Sci. shifted our focus to meet such demand." said The CEO of Aston Sci., Hunwoo Shin, "We strive to increase the clinical value of cancer vaccines through subsequent clinical trials and research, and also focus our capabilities on future business development."
In addition, Aston Sci. has 10 pipelines in various preclinical and clinical stages including AST-301 and AST-021p. By 2030, the company plans to expand its pipeline to 15 drugs in 4 clinical fields, focusing on efficient development of new drugs with high unmet medical needs and high demand in clinical fields.
Aston Sci. decided to list on the KOSDAQ in order to facilitate its clinical and business development, and as part of that, NH Investment & Securities was selected as the listing manager in May. It is in the works, with the goal to list in early 2023 upon receiving technology evaluation within the next year.